Mirum Pharmaceuticals, Inc.

This study tests a new drug, BJT-778, against an existing one (bulevirtide) for chronic hepatitis delta, a serious liver infection. About 172 adults with the virus will receive either drug to see which better controls the virus and normalizes liver enzymes. Participants must alre…

This study tests whether switching from the current drug bulevirtide to a new one called brelovitug can better control chronic hepatitis Delta. About 120 adults who have been on bulevirtide for at least 6 months will take brelovitug for 24 weeks. The main goal is to see if the vi…

This study tests a new medicine called brelovitug for people with chronic hepatitis delta, a serious liver infection. About 80 adults will either get brelovitug right away or wait a bit before starting treatment. The goal is to see if the drug can lower the virus level and improv…

This study follows about 100 people with Alagille syndrome who are taking the medication Livmarli. Researchers want to see how safe the drug is over time and how it affects liver function and overall health. Participants will be monitored for side effects, changes in liver tests,…

This study tests an experimental drug called volixibat to see if it can reduce the intense itching caused by primary biliary cholangitis (PBC), a chronic liver disease. About 260 adults with PBC and moderate to severe itching will receive either volixibat or a placebo daily. The …

This study tests a new drug called MRM-3379 in males aged 13 to 45 with Fragile X Syndrome. The goal is to see if the drug is safe and can improve symptoms. Participants will take the drug or a placebo for 12 weeks. The study involves 60 people at multiple locations.